↓ Skip to main content

Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.

Overview of attention for article published in JCO Precision Oncology, February 2020
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)

Mentioned by

twitter
6 X users

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.
Published in
JCO Precision Oncology, February 2020
DOI 10.1200/po.19.00272
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Other 5 19%
Researcher 4 15%
Student > Postgraduate 3 11%
Student > Master 2 7%
Student > Bachelor 1 4%
Other 1 4%
Unknown 11 41%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 10 37%
Agricultural and Biological Sciences 2 7%
Biochemistry, Genetics and Molecular Biology 1 4%
Immunology and Microbiology 1 4%
Neuroscience 1 4%
Other 0 0%
Unknown 12 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2020.
All research outputs
#11,464,118
of 34,378,656 outputs
Outputs from JCO Precision Oncology
#1,054
of 1,755 outputs
Outputs of similar age
#180,848
of 515,053 outputs
Outputs of similar age from JCO Precision Oncology
#10
of 13 outputs
Altmetric has tracked 34,378,656 research outputs across all sources so far. This one has received more attention than most of these and is in the 65th percentile.
So far Altmetric has tracked 1,755 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.1. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 515,053 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.